The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Pathogenesis and Treatment of Chronic Kidney Disease: A Review of Our Recent Basic and Clinical Data
Open accessAbstract
Chronic kidney disease (CKD) is a worldwide public health problem that affects millions of people from all racial and ethnic groups. At end of 2013, over 300,000 Japanese patients had maintenance dialysis therapy (JSDT). In Japan, the major causes of end stage kidney disease (ESKD) are chronic glomerulonephritis (particularly IgA nephropathy), type 2 diabetic nephropathy, and hypertensive nephrosclerosis. Hypertension is a major factor driving the progression of CKD to ESKD. Since many features of the pathogenesis of IgA nephropathy are still obscure, specific treatment is not yet available. However, efforts by investigators around the world have gradually clarified different aspects of the pathogenesis and treatment of IgA nephropathy. Today, around half of all diabetic patients in Japan receive medical treatment. Type 2 diabetic nephropathy is one of the major long-term microvascular complications occurring in nearly 40% of Japanese diabetic patients. The pathogenesis of diabetic nephropathy involves both genetic and environmental factors. However, the candidate genes related to the initiation and progression of the disorder are still obscure in patients with diabetic nephropathy. Regarding environmental factors, the toxicity of persistent hyperglycemia, reactive oxygen species, systemic and/or glomerular hypertension, dyslipidemia and complement are considered to play an important role. The first part of this review covers the pathogenesis of IgA nephropathy and type 2 diabetic nephropathy, and combines the clinicopathological findings in patients with our research on the ddY and KKA-y mouse models (spontaneous animal models for IgA nephropathy and diabetic nephropathy, respectively). In Japan, the major renal replacement therapies (RRT) are peritoneal dialysis (PD) and hemodialysis (HD). The second part of this review focuses on PD and HD. Based on our research findings from patients and as well as from animal models, we discuss strategies for the management of patients on PD and HD. i 2015 S. Karger AG, Basel
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The TNF and TNF Receptor Superfamilies
Locksley, R. M., Killeen, N., & Lenardo, M. J. (2001) · Cell · doi:10.1016/s0092-8674(01)00237-9 · Cited by 3,650
A Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Cattran, D. C., Coppo, R., Cook, H. T., Feehally, J., Roberts, I. S. D., Troyanov, S., Alpers, C. E., Amore, A., Barratt, J., et al. (2009) · Kidney International · doi:10.1038/ki.2009.243 · Cited by 1,235
Self-citationCombined angiotensin inhibition for the treatment of diabetic nephropathy
Fried, L. F., Emanuele, N., Zhang, J. H., Brophy, M., Conner, T. A., Duckworth, W., Leehey, D. J., McCullough, P. A., O'Connor, T., Palevsky, P. M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303154 · Cited by 1,169
Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy
Parving, H.-H., Persson, F., Lewis, J. B., Lewis, E. J., & Hollenberg, N. K. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708379 · Cited by 1,098
Morphologic Changes in the Peritoneal Membrane of Patients with Renal Disease
Williams, J. D., Craig, K. J., Topley, N., Von Ruhland, C., Fallon, M., Newman, G. R., Mackenzie, R. K., & Williams, G. T. (2002) · Journal of the American Society of Nephrology · doi:10.1681/asn.v132470 · Cited by 959
Donadio, J. V., & Grande, J. P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra020109 · Cited by 661
The structure and function of human IgA
Kerr, M. A. (1990) · Biochemical Journal · doi:10.1042/bj2710285 · Cited by 596
[Intercapillary deposits of IgA-IgG].
Berger, J., & Hinglais, N. (1968) · PubMed · Cited by 533
Tomana, M., Novak, J., Julian, B. A., Matousovic, K., Konecny, K., & Mestecky, J. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5535 · Cited by 498
Circulating TNF Receptors 1 and 2 Predict ESRD in Type 2 Diabetes
Niewczas, M. A., Gohda, T., Skupien, J., Smiles, A. M., Walker, W. H., Rosetti, F., Cullere, X., Eckfeldt, J. H., Doria, A., Mayadas, T. N., et al. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011060627 · Cited by 485
Li, L.-S., & Liu, Z.-H. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00837.x · Cited by 475
Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats.
Vlassara, H., Striker, L. J., Teichberg, S., Fuh, H., Li, Y. M., & Steffes, M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.24.11704 · Cited by 462
Roos, A., Rastaldi, M. P., Calvaresi, N., Oortwijn, B. D., Schlagwein, N., van Gijlswijk-Janssen, D. J., Stahl, G. L., Matsushita, M., Fujita, T., van Kooten, C., et al. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005090923 · Cited by 450
Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy
Foley, R. N., Parfrey, P. S., Morgan, J., Barré, P. E., Campbell, P., Cartier, P., Coyle, D., Fine, A., Handa, P., Kingma, I., et al. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00289.x · Cited by 412
Angiotensin-(1-7) Dilates Canine Coronary Arteries Through Kinins and Nitric Oxide
Brosnihan, K. B., Li, P., & Ferrario, C. M. (1996) · Hypertension · doi:10.1161/01.hyp.27.3.523 · Cited by 404
Tsang, T. S. M., Barnes, M. E., Gersh, B. J., Takemoto, Y., Rosales, A. G., Bailey, K. R., & Seward, J. B. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00943-4 · Cited by 390
Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat
Degenhardt, T. P., Alderson, N. L., Arrington, D. D., Beattie, R. J., Basgen, J. M., Steffes, M. W., Thorpe, S. R., & Baynes, J. W. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00207.x · Cited by 378
Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy
Hiki, Y., Odani, H., Takahashi, M., Yasuda, Y., Nishimoto, A., Iwase, H., Shinzato, T., Kobayashi, Y., & Maeda, K. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00591.x · Cited by 378
Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis
Chan, C. T., Floras, J. S., Miller, J., Richardson, R., & Pierratos, A. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00362.x · Cited by 368
Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG
Tomana, M., Matoušovic, K., Julian, B. A., Radl, J., Konecný, K., & Mestecky, J. (1997) · Kidney International · doi:10.1038/ki.1997.361 · Cited by 341
Hotta, O., Miyazaki, M., Furuta, T., Tomioka, S., Chiba, S., Horigome, I., Abe, K., & Taguma, Y. (2001) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2001.27690 · Cited by 336
IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22–23
Gharavi, A. G., Yan, Y., Scolari, F., Schena, F. P., Frasca, G. M., Ghiggeri, G. M., Cooper, K., Amoroso, A., Viola, B. F., Battini, G. G., et al. (2000) · Nature Genetics · doi:10.1038/81677 · Cited by 332
Natural history and risk factors for immunoglobulin a nephropathy in Japan
Koyama, A., Igarashi, M., & Kobayashi, M. (1997) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(97)90333-4 · Cited by 326
Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: Observations in three patients
Allen, A. C., Bailey, E. M., Brenchley, P. E., Buck, K., Barratt, J., & Feehally, J. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.060003969.x · Cited by 311
Urinary excretion of podocytes in patients with diabetic nephropathy
Nakamura, T., Ushiyama, C., Suzuki, S., Hara, M., Shimada, N., Ebihara, I., & Koide, H. (2000) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/15.9.1379 · Cited by 303
Podocytopenia and disease severity in IgA nephropathy
Lemley, K. V., Lafayette, R. A., Safai, M., Derby, G., Blouch, K., Squarer, A., & Myers, B. D. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00269.x · Cited by 296
The place of human γ-trace (cystatin C) amongst the cysteine proteinase inhibitors
Barrett, A. J., Davies, M. E., & Grubb, A. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(84)91302-0 · Cited by 294
Galactosylation of N- and O-linked carbohydrate moieties of IgA1 and IgG in IgA nephropathy
ALLEN, A. C., HARPER, S. J., & FEEHALLY, J. (2008) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.1995.tb03724.x · Cited by 277
Amadorins: Novel Post-Amadori Inhibitors of Advanced Glycation Reactions
Khalifah, R. G., Baynes, J. W., & Hudson, B. G. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0371 · Cited by 268
Goto, M., Wakai, K., Kawamura, T., Ando, M., Endoh, M., & Tomino, Y. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp273 · Cited by 255
Self-citationNovak, J., Tomana, M., Brown, R., Hall, S., Novak, L., Julian, B. A., Wyatt, R. J., Mestecky, J., & Matousovic, K. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.67107.x · Cited by 228
Cardiovascular disease in patients with chronic kidney disease: Getting to the heart of the matter
Levin, A., Djurdjev, O., Barrett, B., Burgess, E., Carlisle, E., Ethier, J., Jindal, K., Mendelssohn, D., Tobe, S., Singer, J., et al. (2001) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2001.29275 · Cited by 223
Lipoproteins in the DCCT/EDIC cohort: Associations with diabetic nephropathy
Jenkins, A. J., Lyons, T. J., Zheng, D., Otvos, J. D., Lackland, D. T., Mcgee, D., Timothy Garvey, W., Klein, R. L., & The DCCT/EDIC Research Group (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00164.x · Cited by 214
Ca2+Channel Subtypes and Pharmacology in the Kidney
Hayashi, K., Wakino, S., Sugano, N., Ozawa, Y., Homma, K., & Saruta, T. (2007) · Circulation Research · doi:10.1161/01.res.0000256155.31133.49 · Cited by 206
Sano, T., Hiki, Y., Kokubo, T., Iwase, H., Shigematsu, H., & Kobayashi, Y. (2002) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/17.1.50 · Cited by 197
Short-Term Blood Pressure, Noradrenergic, and Vascular Effects of Nocturnal Home Hemodialysis
Chan, C. T., Harvey, P. J., Picton, P., Pierratos, A., Miller, J. A., & Floras, J. S. (2003) · Hypertension · doi:10.1161/01.hyp.0000097605.35343.64 · Cited by 188
Toll-Like Receptor 9 Affects Severity of IgA Nephropathy
Suzuki, H., Suzuki, Y., Narita, I., Aizawa, M., Kihara, M., Yamanaka, T., Kanou, T., Tsukaguchi, H., Novak, J., Horikoshi, S., et al. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007121311 · Cited by 187
Self-citationAberrant glycosylation in IgA nephropathy (IgAN)
Coppo, R., & Amore, A. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.05407.x · Cited by 180
Kawamura, T., Yoshimura, M., Miyazaki, Y., Okamoto, H., Kimura, K., Hirano, K., Matsushima, M., Utsunomiya, Y., Ogura, M., Yokoo, T., et al. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfu020 · Cited by 180
Self-citationA scoring system to predict renal outcome in IgA nephropathy: from a nationwide prospective study
Wakai, K., Kawamura, T., Endoh, M., Kojima, M., Tomino, Y., Tamakoshi, A., Ohno, Y., Inaba, Y., & Sakai, H. (2006) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfl342 · Cited by 178
Self-citationLeft Atrium Size and the Risk of Cardiovascular Death in Middle-aged Men
Laukkanen, J. A., Kurl, S., Eränen, J., Huttunen, M., & Salonen, J. T. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.15.1788 · Cited by 177
Angiotensin-(1–7) prevents diabetes-induced cardiovascular dysfunction
Benter, I. F., Yousif, M. H. M., Cojocel, C., Al-Maghrebi, M., & Diz, D. I. (2007) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00372.2006 · Cited by 167
Kokubo, T., Hiki, Y., Iwase, H., Tanaka, A., Toma, K., Hotta, K., & Kobayashi, Y. (1998) · Journal of the American Society of Nephrology · doi:10.1681/asn.v9112048 · Cited by 166
A Population-based Study of Morbidity and Mortality in Mannose-binding Lectin Deficiency
Dahl, M., Tybjærg-Hansen, A., Schnohr, P., & Nordestgaard, B. G. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040111 · Cited by 163
Steroid Therapy during the Early Stage of Progressive IgA Nephropathy
Kobayashi, Y., Hiki, Y., Kokubo, T., Horii, A., & Tateno, S. (2008) · The Nephron journals/Nephron journals · doi:10.1159/000188848 · Cited by 148
Tashiro, K., Koyanagi, I., Saitoh, A., Shimizu, A., Shike, T., Ishiguro, C., Koizumi, M., Funabïki, K., Horikoshi, S., Shirato, I., et al. (2002) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.2057 · Cited by 141
Self-citationBreeding of Mice Strains for Diabetes Mellitus
Nishimura, M. (1969) · EXPERIMENTAL ANIMALS · doi:10.1538/expanim1957.18.4_147 · Cited by 139
A Panel of Serum Biomarkers Differentiates IgA Nephropathy from Other Renal Diseases
Yanagawa, H., Suzuki, H., Suzuki, Y., Kiryluk, K., Gharavi, A. G., Matsuoka, K., Makita, Y., Julian, B. A., Novák, J., & Tomino, Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098081 · Cited by 138
Self-citationMannan-binding-lectin-associated serine proteases, characteristics and disease associations
Sørensen, R., Thiel, S., & Jensenius, J. C. (2005) · Springer Seminars in Immunopathology · doi:10.1007/s00281-005-0006-z · Cited by 136
Boor, P., Celec, P., Behuliak, M., Grančič, P., Kebis, A., Kukan, M., Prónayová, N., Liptaj, T., Ostendorf, T., & Šebeková, K. (2009) · Metabolism · doi:10.1016/j.metabol.2009.05.025 · Cited by 126
Analysis of Left-Ventricular Changes Associated with Chronic Hemodialysis
Hüting, J., Kramer, W., Schütterle, G., & Wizemann, V. (2008) · The Nephron journals/Nephron journals · doi:10.1159/000185077 · Cited by 116
Gu, L., Hagiwara, S., Fan, Q., Tanimoto, M., Kobata, M., Yamashita, M., Nishitani, T., Gohda, T., Ni, Z., Qian, J., et al. (2005) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfi210 · Cited by 116
Self-citationIo, H., Hamada, C., Ro, Y., Ito, Y., Hirahara, I., & Tomino, Y. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00599.x · Cited by 112
Self-citationXu, L., & Zhao, M. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00390.x · Cited by 96
Fan, Q., Liao, J., Kobayashi, M., Yamashita, M., Gu, L., Gohda, T., Suzuki, Y., Wang, L. N., Horikoshi, S., & Tomino, Y. (2004) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh499 · Cited by 95
Self-citationTanimoto, M., Gohda, T., Kaneko, S., Hagiwara, S., Murakoshi, M., Aoki, T., Yamada, K. H., Ito, T., Matsumoto, M., Horikoshi, S., et al. (2007) · Metabolism · doi:10.1016/j.metabol.2006.08.026 · Cited by 94
Self-citationNakata, J., Suzuki, Y., Suzuki, H., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089707 · Cited by 92
Moon, J.-Y., Tanimoto, M., Gohda, T., Hagiwara, S., Yamazaki, T., Ohara, I., Murakoshi, M., Aoki, T., Ishikawa, Y., Lee, S.-H., et al. (2011) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00065.2010 · Cited by 88
Self-citationHagiwara, S., Makita, Y., Gu, L., Tanimoto, M., Zhang, M., Nakamura, S., Kaneko, S., Itoh, T., Gohda, T., Horikoshi, S., et al. (2005) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfi208 · Cited by 84
Self-citationTh1 polarization in murine IgA nephropathy directed by bone marrow-derived cells
Suzuki, H., Suzuki, Y., Aizawa, M., Yamanaka, T., Kihara, M., Pang, H., Horikoshi, S., & Tomino, Y. (2007) · Kidney International · doi:10.1038/sj.ki.5002300 · Cited by 82
Self-citationRole of the TNF pathway in the progression of diabetic nephropathy in KK-Aymice
Omote, K., Gohda, T., Murakoshi, M., Sasaki, Y., Kazuno, S., Fujimura, T., Ishizaka, M., Sonoda, Y., & Tomino, Y. (2014) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00509.2013 · Cited by 79
Self-citationShimizu, H., Ohtani, K.-I., Tanaka, Y., Sato, N., Mori, M., & Shimomura, Y. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)01056-j · Cited by 65
Glomerular changes in the KK‐Ay/Ta mouse: A possible model for human type 2 diabetic nephropathy
Ito, T., Tanimoto, M., Yamada, K. H., KANEKO, S., Matsumoto, M., OBAYASHI, K., Hagiwara, S., Murakoshi, M., Aoki, T., Wakabayashi, M., et al. (2006) · Nephrology · doi:10.1111/j.1440-1797.2006.00543.x · Cited by 63
Self-citationProposal of remission criteria for IgA nephropathy
Suzuki, Y., Matsuzaki, K., Suzuki, H., Sakamoto, N., Joh, K., Kawamura, T., Tomino, Y., & Matsuo, S. (2013) · Clinical and Experimental Nephrology · doi:10.1007/s10157-013-0849-x · Cited by 62
Self-citationIgA induced activation of human mesangial cells: Independent of FcαR1 (CD 89)
Diven, S. C., Caflisch, C. R., Hammond, D. K., Weigel, P. H., Oka, J. A., & Goldblum, R. M. (1998) · Kidney International · doi:10.1046/j.1523-1755.1998.00054.x · Cited by 60
Novel Biomarkers for the Progression of Diabetic Nephropathy: Soluble TNF Receptors
Gohda, T., & Tomino, Y. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0385-9 · Cited by 45
Self-citationZhang, M., Hagiwara, S., Matsumoto, M., Gu, L., Tanimoto, M., Nakamura, S., Kaneko, S., Gohda, T., Qian, J., Horikoshi, S., et al. (2006) · Metabolism · doi:10.1016/j.metabol.2006.07.019 · Cited by 41
Self-citationTreatment and impact of dyslipidemia in diabetic nephropathy
Toyama, T., Shimizu, M., Furuichi, K., Kaneko, S., & Wada, T. (2013) · Clinical and Experimental Nephrology · doi:10.1007/s10157-013-0898-1 · Cited by 39
Mindin: a novel marker for podocyte injury in diabetic nephropathy
Murakoshi, M., Tanimoto, M., Gohda, T., Hagiwara, S., Takagi, M., Horikoshi, S., & Tomino, Y. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq708 · Cited by 39
Self-citationShimizu, A., Horikoshi, S., Rinno, H., Kobata, M., Saito, K., & Tomino, Y. (2003) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.10087 · Cited by 36
Self-citationOhara, I., Tanimoto, M., Gohda, T., Yamazaki, T., Hagiwara, S., Murakoshi, M., Aoki, T., Toyoda, H., Ishikawa, Y., Funabiki, K., et al. (2010) · Nephron Experimental Nephrology · doi:10.1159/000320284 · Cited by 33
Self-citationOsada, S., Hamada, C., Shimaoka, T., Kaneko, K., Horikoshi, S., & Tomino, Y. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp268 · Cited by 33
Self-citationThe Pathogeneic Role of Immunoglobin APolymers in Immunoglobulin A Nephropathy
Harper, S. J., & Feehally, J. (2008) · The Nephron journals/Nephron journals · doi:10.1159/000187509 · Cited by 32
Genetic associations in diabetic nephropathy
Mooyaart, A. L. (2013) · Clinical and Experimental Nephrology · doi:10.1007/s10157-013-0874-9 · Cited by 31
Impact of Body Mass Index on Progression of IgA Nephropathy Among Japanese Patients
Shimamoto, M., Ohsawa, I., Suzuki, H., et al. (2014) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.21778 · Cited by 27
Pleiotropic effect of pyridoxamine on diabetic complications via CD36 expression in KK-Ay/Ta mice
Murakoshi, M., Tanimoto, M., Gohda, T., Hagiwara, S., Ohara, I., Toyoda, H., Ishikawa, Y., Horikoshi, S., & Tomino, Y. (2009) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.11.008 · Cited by 27
Self-citationBlood group genotyping in a population of highly diverse ancestry
Pellegrino, J., Castilho, L. M., Rios, M., & Souza, C. A. D. (2001) · Journal of Clinical Laboratory Analysis · doi:10.1002/1098-2825(2001)15:1 · Cited by 24
Combination Effects of Enalapril and Losartan on Lipid Peroxidation in the Kidneys of KK-Ay/Ta Mice
Yamazaki, T., Tanimoto, M., Gohda, T., Ohara, I., Hagiwara, S., Murakoshi, M., Matsumoto, M., Kaneko, S., Aoki, T., Toyoda, H., et al. (2009) · Nephron Experimental Nephrology · doi:10.1159/000228714 · Cited by 23
Self-citationIo, H., Matsumoto, M., Okumura, K., Sato, M., Masuda, A., Furukawa, M., Nohara, N., Tanimoto, M., Kodama, F., Hagiwara, S., et al. (2010) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2010.00759.x · Cited by 19
Self-citationFurukawa, M., Io, H., Tanimoto, M., Hagiwara, S., Horikoshi, S., & Tomino, Y. (2010) · Nephron Clinical Practice · doi:10.1159/000321512 · Cited by 18
Self-citationTanaka, M., Suzuki, Y., Shirato, I., Takahara, H., Shibata, T., Sugaya, T., Shimamoto, K., Horikoshi, S., & Tomino, Y. (2008) · Inflammation Research · doi:10.1007/s00011-008-7171-1 · Cited by 17
Self-citationIo, H., Ro, Y., Sekiguchi, Y., Shimaoka, T., Inuma, J., Hotta, Y., Aruga, S., Inami, Y., Sato, M., Kobayashi, T., et al. (2010) · Peritoneal Dialysis International · doi:10.3747/pdi.2009.00007 · Cited by 17
Self-citationRole of Mindin in Diabetic Nephropathy
Murakoshi, M., Gohda, T., Tanimoto, M., Funabïki, K., Horikoshi, S., & Tomino, Y. (2011) · Experimental Diabetes Research · doi:10.1155/2011/486305 · Cited by 15
Self-citationInoshita, H., Ohsawa, I., Kusaba, G., Ishii, M., Onda, K., Horikoshi, S., Ohi, H., & Tomino, Y. (2010) · BMC Nephrology · doi:10.1186/1471-2369-11-34 · Cited by 13
Self-citationAdvanced Glycation End Products and the Pathogenesis of Diabetic Nephropathy
Yamagishi, S., Takeuchi, M., & Makita, Z. (2001) · KARGER eBooks · doi:10.1159/000060150 · Cited by 12
APOE polymorphism and diabetic nephropathy
Araki, S. (2013) · Clinical and Experimental Nephrology · doi:10.1007/s10157-013-0862-0 · Cited by 12
Suzuki, D. T., Miyata, T., & Kurokawa, K. (2001) · KARGER eBooks · doi:10.1159/000060151 · Cited by 12
A Paradigm Shift for the Concept of Diabetic Nephropathy
Gohda, T., & Tomino, Y. (2014) · Juntendō Igaku/Juntendo igaku · doi:10.14789/jmj.60.293 · Cited by 6
Self-citationTomino, Y., Shimizu, Y., Hamada, C., Kurusu, A., Ohsawa, I., Suzuki, Y., Tsuge, T., Io, H., Kobayashi, N., Takeda, Y., et al. (2011) · Journal of Nephrology · doi:10.5301/jn.2011.6383 · Cited by 6
Self-citationShou, I., Fukui, M., & Tomino, Y. (2001) · KARGER eBooks · doi:10.1159/000060135 · Cited by 4
Self-citation
Research works printed but not linked: 60
- 10.1002/jcla.20227 · doi:10.1002/jcla.20227
- 10.5301/jn.5000151 · doi:10.5301/jn.5000151
- 10.1002/jcla.20154 · doi:10.1002/jcla.20154
- 10.5301/jn.5000278 · doi:10.5301/jn.5000278
- 10.1093/ndt/gfs262 · doi:10.1093/ndt/gfs262
- 10.1007/s00795-011-0538-3 · doi:10.1007/s00795-011-0538-3
- 10.1159/000054214 · doi:10.1159/000054214
- 10.1093/ndt/gfs500 · doi:10.1093/ndt/gfs500
- 10.1007/s00011-007-6145-z · doi:10.1007/s00011-007-6145-z
- 10.1038/ki.1985.76 · doi:10.1038/ki.1985.76
- 10.1681/ASN.2004030219 · doi:10.1681/asn.2004030219
- 10.1159/000046067 · doi:10.1159/000046067
- 10.1159/000044994 · doi:10.1159/000044994
- 10.1016/S0272-6386(12)80272-1 · doi:10.1016/s0272-6386(12)80272-1
- 10.1046/j.1523-1755.1999.00750.x · doi:10.1046/j.1523-1755.1999.00750.x
- 10.4049/jimmunol.180.2.1008 · doi:10.4049/jimmunol.180.2.1008
- 10.1111/j.1365-2249.2006.03026.x · doi:10.1111/j.1365-2249.2006.03026.x
- 10.1038/sj.ki.5000074 · doi:10.1038/sj.ki.5000074
- 10.1159/000187984 · doi:10.1159/000187984
- 10.1002/jcla.10071 · doi:10.1002/jcla.10071
- 10.1002/(SICI)1098-2825(1998)12:1<1::AID-JCLA1>3.0.CO;2-F · DOI
- 10.1159/000168359 · doi:10.1159/000168359
- 10.1093/ndtplus/sfp014 · doi:10.1093/ndtplus/sfp014
- 10.1007/s10157-009-0179-1 · doi:10.1007/s10157-009-0179-1
- 10.1093/ndt/gfr403 · doi:10.1093/ndt/gfr403
- 10.1016/j.cca.2012.02.029 · doi:10.1016/j.cca.2012.02.029
- 10.1002/jcla.21608 · doi:10.1002/jcla.21608
- 10.1002/(SICI)1098-2825(1998)12:6<378::AID-JCLA8>3.0.CO;2-J · doi:10.1002/(sici)1098-2825(1998)12:6<378::aid-jcla8>3.0.co;2-j
- 10.1002/jcla.1026 · doi:10.1002/jcla.1026
- 10.1159/000064453 · doi:10.1159/000064453
- 10.1002/1098-2825(2001)15:1<25::AID-JCLA5>3.0.CO;2-Y · doi:10.1002/1098-2825(2001)15:1<25::aid-jcla5>3.0.co;2-y
- 10.1093/ndt/14.suppl_3.1 · doi:10.1093/ndt/14.suppl_3.1
- 10.1590/S0102-86502007000500003 · doi:10.1590/s0102-86502007000500003
- 10.4236/jdm.2012.23054 · doi:10.4236/jdm.2012.23054
- 10.1155/2012/702948 · DOI
- 10.1159/000049428 · doi:10.1159/000049428
- 10.1159/000100498 · DOI
- 10.1016/j.metabol.2008.01.007 · doi:10.1016/j.metabol.2008.01.007
- 10.5551/jat.3764 · doi:10.5551/jat.3764
- 10.1111/j.1463-1326.2012.01566.x · doi:10.1111/j.1463-1326.2012.01566.x
- 10.1155/2013/519130 · doi:10.1155/2013/519130
- 10.1002/jcla.20027 · doi:10.1002/jcla.20027
- 10.1007/s10047-012-0663-3 · doi:10.1007/s10047-012-0663-3
- 10.1159/000183987 · doi:10.1159/000183987
- 10.1159/000169582 · doi:10.1159/000169582
- 10.2215/CJN.03630807 · doi:10.2215/cjn.03630807
- 10.1093/ndt/gfq194 · doi:10.1093/ndt/gfq194
- 10.5414/CNP69121 · doi:10.5414/cnp69121
- 10.1007/s10047-013-0741-1 · doi:10.1007/s10047-013-0741-1
- 10.1093/ndt/17.7.1293 · doi:10.1093/ndt/17.7.1293
- 10.1371/journal.pone.0053382 · doi:10.1371/journal.pone.0053382
- 10.1093/ndt/gfm323 · doi:10.1093/ndt/gfm323
- 10.1111/j.1744-9987.2011.00936.x · doi:10.1111/j.1744-9987.2011.00936.x
- 10.1016/j.molimm.2004.12.006 · doi:10.1016/j.molimm.2004.12.006
- 10.1016/j.molimm.2005.06.018 · doi:10.1016/j.molimm.2005.06.018
- 10.1111/j.1365-2249.2004.02634.x · doi:10.1111/j.1365-2249.2004.02634.x
- 10.2147/IJNRD.S65929 · doi:10.2147/ijnrd.s65929
- 10.1159/000073442 · doi:10.1159/000073442
- 10.1177/000331970005100206 · doi:10.1177/000331970005100206
- 10.1097/00004872-199107000-00003 · doi:10.1097/00004872-199107000-00003
Cited by
Hartleben, B., Gödel, M., Meyer-Schwesinger, C., Liu, S., Ulrich, T., Köbler, S., Wiech, T., Grahammer, F., Arnold, S. J., Lindenmeyer, M. T., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci39492 · Cited by 721
Inflammation-Related Mechanisms in Chronic Kidney Disease Prediction, Progression, and Outcome
Mihai, S., Codrici, E., Popescu, I. D., Enciu, A.-M., Albulescu, L., Necula, L. G., Mambet, C., Anton, G., & Tanase, C. (2018) · Journal of Immunology Research · doi:10.1155/2018/2180373 · Cited by 673
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Abdelhamid, A. S., Brown, T. J., Brainard, J. S., Biswas, P., Thorpe, G. C., Moore, H. J., Deane, K. H., AlAbdulghafoor, F. K., Summerbell, C. D., Worthington, H. V., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003177.pub3 · Cited by 630
Diabetic nephropathy – complications and treatment
Lim, A. (2014) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s40172 · Cited by 583
mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice
Inoki, K., Mori, H., Wang, J., Suzuki, T., Hong, S., Yoshida, S., Blattner, S. M., Ikenoue, T., Rüegg, M. A., Hall, M. N., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44771 · Cited by 538
Metadata
- Authors
- Tomino, Y.
- Venue
- Kidney and Blood Pressure Research
- Publisher
- S. Karger AG
- Published
- 2014
- Volume
- 39
- Issue
- 5
- Pages
- 450-489
- ISSN
- 1420-4096 (ISSN-L)
- 1423-0143
- OpenAlex
- W2029774820
- Cited by
- 566
- References
- 90
- FWCI
- 44.43
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- creativecommons.org/licenses/by-nc/3.0/ (vor)
- creativecommons.org/licenses/by-nc/3.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.